|Name:||Bruce L. Levine, Ph.D.|
|Title/Titles:||Barbara and Edward Netter Professor in Cancer Gene Therapy Director, Clinical Cell and Vaccine Production Facility Research Associate Professor, Department of Pathology and Laboratory Medicine|
Dr. Levine is an alumnus of the University of Pennsylvania. He began his scientific career at the Wistar Institute during summers in high school and while an undergraduate at Penn. While there, he learned cell culture in the laboratory of Dr. Vincent Cristofalo. After graduation in 1984, he worked as a technician in the Division of Infectious Diseases at the Children's Hospital of Philadelphia examining immune responses following Varicella (Chicken Pox) vaccination.
Dr. Levine received his Ph. D. in Immunology and Infectious Diseases from the Johns Hopkins University in 1992. He was a post-doctoral fellow with Dr. Carl June at the Naval Medical Research Institute in Bethesda, MD and later an Investigator at NMRI and Research Assistant Professor of Medicine at the Uniformed Services University for the Health Sciences. During this time, he developed a system for large scale efficient culture of lymphocytes that has proved to be the foundation for several current Phase I clinical trials of adoptive immunotherapy for infection or malignancy at the Abramson Cancer Center at the University of Pennsylvania.
He is currently Director of the Clinical Cell and Vaccine Production Facility which activates, inserts potentially therapeutic genes and expands patient immune system cells ex vivo as a way to re-educate the immune system to better fight residual cancer or infection. The CVPF is accredited by the Foundation for the Accreditation of Cellular Therapy. A second part of the role of the CVPF in supporting new clinical trials is the scale-up and validation of large-scale cell processing procedures for the next generation of cell therapy trials. The third aspect of the CVPF mission is to study immune status from patient samples pre- and post-treatment to delve into the mechanisms of engineered tumor and HIV immunity. The CVPF has produced over 500 cell therapy products for over 300 patients in 22 completed or ongoing Phase I and randomized clinical trials, and conducted the first trial of lentiviral vector-modified cells. Dr. Levine maintains research interests in lymphocyte growth, activation and senescence, and HIV immunity.
Porter, D.L., Levine, B.L., Bunin, N., Stadtmauer, E.A. Luger, S.M. Goldstein, S., Loren, A., Phillips, J., Nasta, S., Perl, A., Schuster, S., Tsai, D., Sohal, A., Veloso, E., Emerson, S., June, C.H.: A Phase I Trial of Donor Lymphocyte Infusions Expanded and Activated Ex-Vivo Via CD3/CD28 Co-Stimulation. Blood 107(4): 1325-1331, February 2006 Notes: prepublished online November 3, 2005; DOI 10.1182/blood-2005-08-3373.
Rapoport, A.P., Stadtmauer, E.A., Aqui, N., Badros, A., Cotte, J., Chrisley, L., Veloso, E., Zheng, Z., Westphal, S., Mair, R., Chi, N., Ratterree, B., Pochran, M.F., Natt, S., Hinkle, J., Sickles, C., Sohal, A., Ruehle, K., Lynch, C., Zhang, L., Porter, D.L., Luger, S., Guo, C., Fang, H.B., Blackwelder, W., Hankey, K., Mann, D., Edelman, R., Frasch, C., Levine, B.L., Cross, A., June, C.H.: Restoration of Immunity in Lymphopenic Cancer Patients by Vaccination and Adoptive T Cell Transfer. Nature Medicine 11(11): 1230-1237, November 2005 Notes: Published online: 16 October 2005; | doi:10.1038/nm1310.
Godfrey, W.R., Spoden, D.J., Ge, Y.G., Baker, S.R., Liu, B., Levine, B.L., June, C.H., Blazar, B.R., Porter, S.B.: Cord Blood CD4+CD25+ Derived T Regulatory Cell Lines Express FoxP3 protein and Manifest Potent Suppressor Function. Blood 105(2): 750-758, January 2005 Notes: pre-published online September 16, 2004 DOI 10.1182/blood-2004-06-2467.
Godfrey, W.R., Ge, Y., Spoden, D.J., Levine, B.L., June, C.H., Blazar, B.R., Porter, S.B.: In Vitro Expanded Human CD4+CD25+ T Regulatory Cells Markedly Inhibit Allogeneic Dendritic Cell Stimulated MLR Cultures. Blood 104(2): 453-61, July 2004 Notes: prepublished online March 18, 2004; DOI 10.1182/blood-2004-01-0151.
Rapoport, A.P., Levine, B.L., Badros, A., Meisenberg, B., Ruehl, K., Nandi, A., Rollins, S., Natt, S., Ratterree, B., Westphal, S., Mann, D., June, C.: Molecular Remission of CML after Autotransplantation Followed by Adoptive Transfer of Costimulated Autologous T-Cells. Bone Marrow Transplantation 33: 53-60, 2004 Notes: prepublished online October 27, 2003; DOI:10.1038/sj.bmt.1704317.
Dropulic, B., Humeau, L., Slepushkin, V., Lu, X., Manilla, P., Rebello, T., Afable, C., Lacy, K., Ybarra, C., Levine, B., June, C., MacGregor, R.R.: Establishing Safety in the Clinic for the First Lentiviral Vector To Be Tested in Humans. Blood 104(11), November 2004 Notes: Abstract of the American Society of Hematology Meeting, 2004.
Bernstein, W.B., Cox, J.H., Aronson, N.E., Tracy, L., Schlienger, K., Ratto-Kim, S., Garner, R., Cotte, J., Zheng, Z., Winestone, L., Liebig, C., Galley, L.M., Connors, M., Birx, D.L., Carroll, R.G., Levine, B.L.: Immune Reconstitution Following Autologous Transfers of CD3/CD28 Stimulated CD4+ T Cells to HIV-Infected Persons. Clinical Immunology 111: 262-274, 2004.
Levine BL., Bernstein WB., Aronson NE., Schlienger K., Cotte J., Perfetto S., Humphries MJ., Ratto-Kim S., Birx DL., Steffens C., Landay A., Carroll RG., June CH.: Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nature Medicine 8(1): 47-53, Jan 2002.
Carroll RG., Riley JL., Levine BL., Feng Y., Kaushal S., Ritchey DW., Bernstein W., Weislow OS., Brown CR., Berger EA., June CH., St Louis DC.: Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 276(5310): 273-6, Apr 11 1997.
Levine BL., Mosca JD., Riley JL., Carroll RG., Vahey MT., Jagodzinski LL., Wagner KF., Mayers DL., Burke DS., Weislow OS., St Louis DC., June CH.: Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272(5270): 1939-43, Jun 28 1996.